The ASGO Experience With Evidence-Based Clinical Practice Guidelines

Thomas J. Smith, Mark R. Somerfield

Research output: Contribution to journalArticlepeer-review

Abstract

After strong demand from members, the American Society of Clinical Oncology (ASCO) began, in 1992, to formulate clinical practice guidelines. Guidelines were written for the following: outcomes from cancer treatment, hematopoietic colony-stimulating factors, tumor markers for breast and colorectal cancer, surveillance of breast cancer patients, and management of non-small-cell lung cancer. Further guidelines are being drafted for management of advanced prostate cancer, antiemetics, bisphosphonates in breast cancer and myeloma, chemoprotectants, and surveillance of colorectal cancer patients. This article explores the process by which ASCO guidelines are drafted, as well problems with these guidelines. Suggestions are made for ASCO and other professional groups that anticipate framing a set of guidelines.

Original languageEnglish (US)
Pages (from-to)223-227
Number of pages5
JournalONCOLOGY
Volume11
Issue number11 SUPPL. 11A
StatePublished - Dec 1 1997
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The ASGO Experience With Evidence-Based Clinical Practice Guidelines'. Together they form a unique fingerprint.

Cite this